paroxysm

(redirected from paroxysmal)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

paroxysm

Pathol
a. a sudden attack or recurrence of a disease
b. any fit or convulsion
Collins Discovery Encyclopedia, 1st edition © HarperCollins Publishers 2005
The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.

Paroxysm

 

a sudden exacerbation of a disease. Examples of symptoms that can accompany paroxysms are attacks of pain in angina pectoris, palpitation in paroxysmal tachycardia, coughing in whooping cough, fever in malaria, and hemolysis in paroxysmal hemoglobinuria. The term “paroxysm” is also used to refer to a sudden outburst of emotion, as in “paroxysm of anger” and “paroxysm of despair.”

The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.

paroxysm

[′par·ək‚siz·əm]
(medicine)
A sudden attack, or the periodic crisis in the progress of a disease.
A spasm, convulsion, or seizure.
A burst of electrical activity during electroencephalography in the form of spikes, or spikes and waves, which indicates cerebral dysrhythmia or epileptic discharges.
(psychology)
A sudden, uncontrollable emotional outburst.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Benign paroxysmal positional vertigo after decompression sickness: a first case report and review of the literature.
Follow-up study of serum S100 protein concentrations demonstrated absence of normalization in the parameter in patients with psychomotor retardation and paroxysmal syndrome, no normalization of MDA level found in examinees with EBD and psychomotor retardation.
Paroxysmal tonic upgaze of childhood and childhood absence epilepsy.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal hematopoietic stem cell disorder, which is caused by a somatic mutation in the phosphatidylinositol glycan-complementation class A gene, with an estimated prevalence of 1-2 cases per million people in the United States (1-2).
The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 5.8 billion by 2025 at an 11.2% CAGR during the forecast period, according to a new report by Grand View Research, Inc.
One-Year Efficacy of Ravulizumab (ALXN1210) in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors, EHA Congress, June 13-16, 2019 Amsterdam, Netherlands, oral presentation, June 15, 2019, 12:00 p.m., abstract S863.
Classification, diagnostic criteria and management of benign paroxysmal positional vertigo.
Diagnosis and management of benign paroxysmal positional vertigo (BPPV).
A prespecified meta-analysis found high sensitivity and low specificity for paroxysmal cough (sensitivity, 93.2%; specificity, 20.6%) and absence of fever (sensitivity, 81.8%; specificity, 18.8%).
United States Food and Drug Administration (USFDA) has approved Ultomiris (ravulizumab) injection intended for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria, it was reported yesterday.
To the Editor: Clinical symptom spectrum of paroxysmal nocturnal hemoglobinuria (PNH) is consisted of chronic intravascular hemolysis, hemoglobinuria, relative bone marrow failure, and the rarity of thrombosis.[1] The neurological complications generated by PNH were almost exclusively a result of cerebral venous thrombosis.[1],[2],[3] However, moyamoya syndrome (MMS) secondary to PNH (PNH-MMS) is rarely described in the literature.[2],[3],[4],[5] We report herein a case of PNH-MMS to raise the awareness of this disease in PNH patients presenting with acute neurological deficits.